Evidence mapPaperPMID 38216693Full record

ReviewNature reviews. Cardiology2024

Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease.

Gabrielle Fredman, Charles N Serhan

Abstract readReview
In one paragraph

Review in Nature reviews. Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed.

  1. SynbioticNutrients · 2024
    Trial
  2. Review
  3. Observational
  4. Luteolin alleviates inflammation by inhibiting the PI3K-Akt-FOXO3a pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Antibody-Empowered Nanomedicine for Precise Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  18. Article
  19. Inflammation and Resolution in Obesity-Related Cardiovascular Disease.International journal of molecular sciences · 2026
    Review
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gabrielle FredmanDepartment of Molecular and Cellular Physiology, Albany Medical College, Albany, NY, USA. fredmag@amc.edu.ORCID 0000-0001-9974-0962
Charles N SerhanCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anaesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4627-8545

Funding

Evaluating Resolution Mechanisms for Infectious InflammationR35GM139430 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 2021 to 2025
$3.6M
Inflammation-resolution impairments in aging and atherosclerosisR01HL170249 · NHLBI · ALBANY MEDICAL COLLEGE · PI Gabrielle Fredman, Katherine C MacNamara · 2023 to 2026
$3.2M
Senescence dysregulates of inflammation-resolution programs in atherosclerosisR01HL153019 · NHLBI · ALBANY MEDICAL COLLEGE · PI FREDMAN, GABRIELLE · 2020 to 2023
$2.6M
NHLBI NIH HHS R01 HL153019NHLBI NIH HHS R01 HL170249NIGMS NIH HHS R35 GM139430
6 · The paper itself

Abstract

Timely resolution of the acute inflammatory response (or inflammation resolution) is an active, highly coordinated process that is essential to optimal health. Inflammation resolution is regulated by specific endogenous signalling molecules that function as 'stop signals' to terminate the inflammatory response when it is no longer needed; to actively promote healing, regeneration and tissue repair; and to limit pain. Specialized pro-resolving mediators are a superfamily of signalling molecules that initiate anti-inflammatory and pro-resolving actions. Without an effective and timely resolution response, inflammation can become chronic, a pathological state that is associated with many widely occurring human diseases, including atherosclerotic cardiovascular disease. Uncovering the mechanisms of inflammation resolution failure in cardiovascular diseases and identifying useful biomarkers for non-resolving inflammation are unmet needs. In this Review, we discuss the accumulating evidence that supports the role of non-resolving inflammation in atherosclerosis and the use of specialized pro-resolving mediators as therapeutic tools for the treatment of atherosclerotic cardiovascular disease. We highlight open questions about therapeutic strategies and mechanisms of disease to provide a framework for future studies on the prevention and treatment of atherosclerosis.

Indexed as

AtherosclerosisInflammation MediatorsAnimalsAnti-Inflammatory AgentsHumansInflammationSignal TransductionAnti-Inflammatory AgentsInflammation Mediators

Identifiers

PMID38216693
PMCPMC12863063

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.